ADVFN - Advanced Financial Network.
HOME» NYSE » M » MDT Stock Price » MDT Stock News

Medtronic Share News

 Medtronic, Inc. Stock Price
MDT Stock Price
 Medtronic, Inc. Stock Chart
MDT Stock Chart
 Medtronic, Inc. Stock News
MDT Stock News
 Medtronic, Inc. Company Information
MDT Company Information
 Medtronic, Inc. Stock Trades
MDT Stock Trades

St. Jude Seeks Retraction Of Riata Study

DOW JONES NEWSWIRES St. Jude Medical Inc. (STJ) said it is seeking a retraction of a study published in a medical journal last month that found heart-defibrillator wires made by the company were responsible for at least 20 deaths, citing inaccurate facts and biased analysis. In the Heart Rhythm Journal last month, prominent cardiologist Robert G. Hauser wrote that separate Riata leads, used in the company's implantable defibrillators, are responsible for the deaths because of "high-voltage failures." Hauser said the deaths allegedly caused by Riata malfunctions were about nine times greater than a competing lead called the Quattro Secure made by Medtronic Inc. (MDT). The medical device company had previously said Hauser's article contains several errors and argued that the Quattro Secure contains different materials from those of Riata. On Friday, St. Jude said Hauser's research substantially undercounted total deaths on the U.S. Food and Drug Administration's device database, called MAUDE, for Quattro Secure, which resulted in errors comparing Riata leads to the Quattro Secure lead. The company said its independent search of the MAUDE database found 377 reports of deaths involving Quattro Secure leads, while Hauser reported 62. The company's analysis of Riata lead events in the database found 74 deaths, while Hauser reported 71. St. Jude also said Hauser's analysis of "lead-related" deaths is biased against companies that are more transparent in reporting on device malfunctions and said its comparison of Riata leads to Quattro Secure is "flawed," given the devices' different materials. St. Jude also said the method of the study, using MAUDE reports to compare devices, "is not appropriate," noting the FDA site says the data are "not intended to be used either to evaluate rates of adverse events or to compare adverse event occurrence rates across devices." Hauser wasn't immediately available to respond to a call for comment. The Riata leads are no longer on the market but are still implanted in about 128,000 patients world-wide. The U.S. Food and Drug Administration has termed the defibrillator issues a Class I recall, which applies to grave dangers like chance of death. On Wednesday, St. Jude said that it would stop selling its QuickSite and QuickFlex left-ventricular leads used to connect cardiac resynchronization therapy devices to the heart, following reports of wires wearing through their silicone covering. Cardiac resynchronization therapy devices are used to help the heart beat more efficiently, while defibrillators are designed to deliver life-saving shocks when needed. St. Jude shares closed at $40.97 Thursday and are up 19% since the start of the year. -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

Stock News for Medtronic (MDT)
DateTimeHeadline
05/21/201515:42:40Medtronic CEO Omar Ishrak to Speak at Sanford Bernstein Strategic...
05/20/201512:15:10What Is the S&P 500 Index?
05/20/201510:40:00China Diabetes Management Devices Market Growth to be Driven...
05/20/201510:40:00China Diabetes Management Devices Market Growth to be Driven...
05/20/201509:30:15Medtronic Drug-Coated Balloon for Treatment of Peripheral Arterial...
05/19/201510:10:11Medtronic Expects Profit at High End of Outlook
05/19/201509:58:11Medtronic Expects Profit at High End of Outlook
05/19/201508:52:17CORRECTION: Medtronic Announces Preliminary Fourth Quarter and...
05/19/201508:35:11Current Report Filing (8-k)
05/19/201508:30:41Medtronic Announces Preliminary Fourth Quarter and Fiscal Year...
05/18/201509:00:00Data Show Medtronic Quadripolar CRT Technology Optimizes Treatment...
05/17/201510:04:024 Reasons Why MannKind Could Succeed Where Pfizer Failed
05/15/201513:30:32Medtronic TYRX(TM) Antibacterial Envelope Reduces Cardiac Device...
05/15/201508:00:00Global Clinical Trial Finds Medtronic Micra® Transcatheter Pacemaker...
05/14/201513:30:28Global Trial Finds Medtronic Micra® Transcatheter Pacemaker...
05/14/201513:30:24Medtronic Evera MRI ICD Clinical Study Meets Safety and Efficacy...
05/13/201510:48:04Dividend Stocks: What You Need to Know
05/13/201509:05:03Dividend Stocks: What You Need to Know
05/12/201515:30:33Medtronic Reiterates Announcement Timing of Its Fourth Quarter...
05/12/201510:00:38Medtronic Receives FDA Approval and CE Mark for Arctic Front...

Medtronic and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad